[(2R,4S,5R)-3,4-dihydroxy-5-(6-methylidene-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷酸
• 英文名称: [(2R,4S,5R)-3,4-dihydroxy-5-(6-methylidene-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
• 化学式: C₁₁H₁₅N₄O₇P
• 分子量: 346.23
• InChiKey: BXSALIGBABHKGL-DZNMIZDJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.4
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  159
• 氢给体数：
  5
• 氢受体数：
  9

文献信息

• [EN] INOSINE MONOPHOSPHATE AND SALTS THEREOF FOR USE IN THE TREATMENT OF COMPLEMENT-RELATED DISORDERS<br/>[FR] MONOPHOSPHATE D'INOSINE ET SES SELS POUR UNE UTILISATION POUR LE TRAITEMENT DE TROUBLES LIÉS AU COMPLÉMENT
  申请人：AMC AMSTERDAM

  公开号：WO2014096958A1

  公开（公告）日：2014-06-26

  The present invention relates to the identification of novel compounds that counteract the formation of the Membrane Attack Complex (MAC) which is the terminal process during complement activation of the immune system, and that is involved in the breakdown of nerves during neurodegenerative diseases. MAC is also deposited after nerve disorders such as traumatic brain injuries and the identified compounds according to the invention are also suitable for the treatment of such disorders. The invention further relates to inosine monophosphate (IMP) and functional equivalent s thereof for use in the treatment, prevention, alleviation or inhibition of disorders mediated by undesired effects of the complement system, such as acute and chronic nerve injuries, preferably to promote axonal regeneration after such injuries have occurred.